AUPH vs. CYRX, YMAB, IGMS, AMRN, KROS, FOLD, BHVN, ARWR, IDYA, and XENE
Should you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include Cryoport (CYRX), Y-mAbs Therapeutics (YMAB), IGM Biosciences (IGMS), Amarin (AMRN), Keros Therapeutics (KROS), Amicus Therapeutics (FOLD), Biohaven (BHVN), Arrowhead Pharmaceuticals (ARWR), IDEAYA Biosciences (IDYA), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical preparations" industry.
Aurinia Pharmaceuticals (NASDAQ:AUPH) and Cryoport (NASDAQ:CYRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking, risk, valuation and institutional ownership.
In the previous week, Cryoport had 1 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 4 mentions for Cryoport and 3 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.10 beat Cryoport's score of 0.09 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.
36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Cryoport shares are held by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 10.1% of Cryoport shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Aurinia Pharmaceuticals currently has a consensus target price of $10.00, indicating a potential upside of 88.68%. Cryoport has a consensus target price of $18.25, indicating a potential upside of 64.41%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than Cryoport.
Aurinia Pharmaceuticals has a net margin of -32.69% compared to Cryoport's net margin of -50.17%. Aurinia Pharmaceuticals' return on equity of -15.06% beat Cryoport's return on equity.
Aurinia Pharmaceuticals has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.
Aurinia Pharmaceuticals has higher earnings, but lower revenue than Cryoport. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Cryoport, indicating that it is currently the more affordable of the two stocks.
Aurinia Pharmaceuticals received 329 more outperform votes than Cryoport when rated by MarketBeat users. Likewise, 73.07% of users gave Aurinia Pharmaceuticals an outperform vote while only 65.21% of users gave Cryoport an outperform vote.
Summary
Aurinia Pharmaceuticals beats Cryoport on 11 of the 18 factors compared between the two stocks.
Get Aurinia Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurinia Pharmaceuticals Competitors List
Related Companies and Tools
